deltatrials
Unknown PHASE3 NCT00008281

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

A Multicenter, Open-Label, Randomized, Three-Arm Study Of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) Or Oxaliplatin Or A Combination Of (5-Fu) LV + Oxaliplatin As Second-Line Treatment Of Metastatic Colorectal Carcinoma

Sponsor: Sanofi

Conditions Colorectal Cancer
Interventions FOLFOX regimen fluorouracil leucovorin calcium oxaliplatin
Updated 6 times since 2017 Last updated: Jan 3, 2014 Started: Oct 31, 2000

A PHASE3 clinical study on Colorectal Cancer, this trial is ongoing. The trial is conducted by Sanofi and has accumulated 6 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE3

    First recorded

Oct 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States, Albany, United States, Arcadia, United States, Aurora, United States, Austin, United States, Baton Rouge, United States, Beaver, United States, Belleville, Canada, Boca Raton, United States, Buffalo, United States and 103 more location s